Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. - Wikidata - wikimedia - TriplyDB

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

http://www.wikidata.org/entity/Q37351764

about

Choosing the right cell line for renal cell cancer research DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells.Erythropoietin and cancer: the unintended consequences of anemia correction Far-western blotting as a solution to the non-specificity of the anti-erythropoietin receptor antibody How Does a Patient's Primary Renal Disease Impact Chronic Dialysis Management?: Patients with Autosomal Dominant Polycystic Kidney Disease.In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography.Erythropoietin and Its Angiogenic Activity.Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma

P2860

Q28073283-F347D990-21A2-4FFD-9033-1DB1E987D74A Q34374689-400437DB-C64E-4223-9F4E-D8BDBB5A338D Q34488415-8055CA62-D39A-49EC-B195-7632BE8D20D5 Q37107771-8BD6F93D-81AB-4098-BD10-6453DA44E06A Q38503184-1E7026AC-CE03-44D4-9733-01648E14467F Q38958980-25F134A4-91C2-456C-A5B5-E17646A95113 Q39432541-94005684-E7A7-48F9-AE45-AC28E5F5BE0B Q39549735-D0C2EB7E-2D94-4ECE-A724-F705CF595C26 Q53120576-AABCEC64-E99A-4E3A-9817-633FB6A80D49 Q58585040-91BF3859-A224-4A63-A630-F1BEEE6B596B

P2860

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

http://www.wikidata.org/entity/Q37351764

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Erythropoietin is a JAK2 and E ...... tion under hypoxic conditions.

@en

Erythropoietin is a JAK2 and E ...... tion under hypoxic conditions.

@nl

type

label

Erythropoietin is a JAK2 and E ...... tion under hypoxic conditions.

@en

Erythropoietin is a JAK2 and E ...... tion under hypoxic conditions.

@nl

prefLabel

Erythropoietin is a JAK2 and E ...... tion under hypoxic conditions.

@en

Erythropoietin is a JAK2 and E ...... tion under hypoxic conditions.

@nl

P1433

Q37351764-1ED93DA1-3C47-4DD0-9976-C90045EAB520

P1476

Q37351764-0EB45028-2A50-4995-8359-27E2AEF326C9

P2093

Q37351764-96030DE7-DA1F-4099-A98B-F6D9D86DECB0

Q37351764-982BF9C9-1470-487C-B304-5252919CC28F

Q37351764-9F1374AA-F64E-4A58-9F83-66E3450D855E

Q37351764-BD30E826-0BFF-4782-A4F5-CFF9A6EEA01C

Q37351764-DAECFFDC-B709-4675-AC88-D98211CD8A00

Q37351764-E034F455-20D3-4020-8E7B-958AE27164CC

P2860

Q37351764-0E6021BA-A1C9-4925-B2CF-9C34F32C46E0

Q37351764-0E7A8769-6E1C-47E4-8E2D-FE0A164BAFB4

Q37351764-0FA82960-B8A3-473D-976A-A3D72A6C6667

Q37351764-1044DF4C-4839-4B24-9BE0-A8342642CC9A

Q37351764-116BF13D-EDD0-4673-B927-E0393B3D8DBD

Q37351764-13633F80-1460-4065-B1DA-FE4B00542337

Q37351764-1AB3EBE4-059B-404B-86F2-B2E783AA11DB

Q37351764-26D2AC6A-B849-4AFA-9F26-BCAED157581D

Q37351764-28DF05E7-6007-49FA-8F64-95C6AC8616B5

Q37351764-2AF6EDCF-EBE4-4B94-BA9F-07E123461BA8

P2888

Q37351764-0DDD3B90-4FB2-4ECC-95D0-051B0898D421

P304

Q37351764-3EC94564-C263-4BBC-B02C-C0A471AB89ED

P31

Q37351764-1474ACB2-9502-4B80-B574-A017DBB2464F

P356

Q37351764-F0BE67E3-4679-4BF3-9FEF-AFF94AA780D7

P478

Q37351764-286C3D09-1C76-4CB8-B2F4-522284682DB7

P577

Q37351764-00E6AC47-9789-4DF9-BB5C-96DEB5702E04

P5875

Q37351764-8304E191-F577-4D2B-B153-D1A4F1C328CD

P6179

Q37351764-E4752119-D340-452B-ADD2-FB44D6C8F955

P698

Q37351764-3B4F90E4-7E3E-4C14-8875-A37C5AE219E3

P921

Q37351764-2E2E9600-3F4C-48F0-8569-9191E391BE5B

Q37351764-FA89B136-2C98-4C70-A229-E0E867699F34

P932

Q37351764-560F6820-574B-421A-8268-734BD27AEFFE

P356

P1433

Journal of Hematology & Oncology

P1476

Erythropoietin is a JAK2 and E ...... tion under hypoxic conditions.

@en

P2093

Adrienne Lawton

http://www.w3.org/2001/XMLSchema#string

Charles J Rosser

http://www.w3.org/2001/XMLSchema#string

Evan Gomes-Giacoia

http://www.w3.org/2001/XMLSchema#string

Ge Zhang

http://www.w3.org/2001/XMLSchema#string

Makito Miyake

http://www.w3.org/2001/XMLSchema#string

Steve Goodison

http://www.w3.org/2001/XMLSchema#string

P2860

Hypoxia-inducible factors in physiology and medicine

Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function

JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin

The erythropoietin receptor in normal and cancer tissues

Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1

Development and characterization of novel erythropoiesis stimulating protein (NESP)

Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein

The molecular biology of erythropoietin

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

Identification of genes periodically expressed in the human cell cycle and their expression in tumors

P2888

P304

65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-8722-6-65

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256448408

http://www.w3.org/2001/XMLSchema#string

P6179

1031381242

http://www.w3.org/2001/XMLSchema#string

P698

24004818

http://www.w3.org/2001/XMLSchema#string

P921

P932

3844377

http://www.w3.org/2001/XMLSchema#string